371 related articles for article (PubMed ID: 8823330)
1. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
[TBL] [Abstract][Full Text] [Related]
2. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
3. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system.
Swanson G; Bergstrom K; Stump E; Miyahara T; Herfindal ET
J Clin Oncol; 2000 Apr; 18(8):1764-70. PubMed ID: 10764438
[TBL] [Abstract][Full Text] [Related]
4. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Bishop MR; Tallman MS; Somerfield MR; Feinglass J; Smith TJ
Ann Oncol; 1999 Nov; 10(11):1355-9. PubMed ID: 10631465
[TBL] [Abstract][Full Text] [Related]
5. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
8. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
9. Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan.
Tamura K
Fukuoka Igaku Zasshi; 1999 Jun; 90(6):279-85. PubMed ID: 10423924
[TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor use in cancer patients.
Baker J; McCune JS; Harvey RD; Bonsignore C; Lindley CM
Ann Pharmacother; 2000; 34(7-8):851-7. PubMed ID: 10928394
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
14. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of colony-stimulating factor use in US academic health centers.
Yim JM; Matuszewski KA; Vermeulen LC; Ratko TA; Burnett DA; Vlasses PH
Ann Pharmacother; 1995 May; 29(5):475-81. PubMed ID: 7544655
[TBL] [Abstract][Full Text] [Related]
16. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Herbst C; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD003189. PubMed ID: 18843642
[TBL] [Abstract][Full Text] [Related]
17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
18. Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group.
Parsons SK; Mayer DK; Alexander SW; Xu R; Land V; Laver J
J Pediatr Hematol Oncol; 2000; 22(3):227-41. PubMed ID: 10864054
[TBL] [Abstract][Full Text] [Related]
19. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (1):CD003189. PubMed ID: 14974009
[TBL] [Abstract][Full Text] [Related]
20. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2002; (4):CD003189. PubMed ID: 12519588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
